Liraglutide 5mg Dosage & Mixing Guide

What is Liraglutide?

Liraglutide is a GLP-1 receptor agonist — a 31-amino-acid analog of human GLP-1 carrying a C16 palmitic acid chain attached via a glutamic acid spacer. That fatty acid does the heavy lifting: it drives self-association into heptamers at the injection site and binds albumin in plasma, which slows absorption and shields the molecule from DPP-4. The result is an elimination half-life of roughly 13 hours instead of the couple of minutes native GLP-1 manages.

Thirteen hours is long enough for daily dosing and nothing more. That is the single most important fact about this compound and it is what separates it from the weekly ladder that semaglutide, tirzepatide, and retatrutide sit on. Liraglutide escalates 0.6 -> 1.2 -> 1.8 -> 2.4 -> 3.0mg, one step per week, injected every single day. It also predates all of them, so the literature is deep human clinical data rather than the animal-and-inference picture most of this catalogue runs on. Older search traffic still finds it under its trade names, Saxenda and Victoza; the molecule is the same liraglutide either way.

For a 5mg vial the daily cadence has a blunt consequence: at the 3.0mg maintenance step, 5mg is under two days of material. This vial size fits the bottom of the escalation ladder, not the top.

Reconstitution

Liraglutide reconstitutes with bacteriostatic water. Draw 2mL down the inside wall of the vial, swirl gently until the solution is clear, and refrigerate. Do not shake — the palmitoylated backbone is surfactant-like and will foam readily.

Quick Reference

Reconstitution Guide

Materials Needed

• Liraglutide 5mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare workspace — Clean environment, gather materials, thorough handwashing.
2. Clean vial stoppers — Wipe both vials with alcohol swabs. Allow complete drying.
3. Draw BAC water — Draw 2mL bacteriostatic water using a sterile syringe.
4. Add to peptide — Inject slowly down the inside wall of the vial. Do not spray directly onto the powder.
5. Dissolve — Allow a few minutes for complete dissolution. Gentle swirl only — no shaking, and expect foam if you rush it.
6. Verify — Solution should be clear and colourless.
7. Label and store — Note reconstitution date. Refrigerate immediately.

Dosage Protocol

Concentration Calculations

With 5mg peptide in 2mL BAC water:

• Concentration: 5mg / 2mL = 2.50mg/mL (2500mcg/mL)
• Per unit (U-100 syringe): 2.50 x 1000 / 100 = 25mcg per unit

Run your exact vial and water combination through the peptide reconstitution calculator to rebuild this table for your setup.

Common Dose Calculations

The 3.0mg top step lands at 1.20mL, or 120 units, which overruns a single U-100 syringe. At that point either split it into two draws or reconstitute in a smaller volume — the 10mg vial at 5mg/mL puts 3.0mg back inside one syringe at 60 units.

Doses Per Vial

Daily dosing makes vial arithmetic matter far more than it does on a weekly compound. Nominal doses from 5mg, before dead space and overfill:

A full 0.6 -> 3.0mg escalation burns roughly 4.2mg in week one and 21mg per week at maintenance. Practical read: the 5mg vial covers the opening week of a titration comfortably and very little after that. See doses per vial, overfill and dead space for why the real count usually runs slightly above these figures.

Research Considerations

Mechanism

Liraglutide binds the GLP-1 receptor and reproduces the incretin signal: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and hypothalamic appetite signalling. Because it clears in about 13 hours, exposure oscillates through the day rather than sitting at the flat plateau a weekly agonist produces — a genuinely different pharmacological shape, and one reason the daily compounds and weekly compounds are not interchangeable milligram for milligram.

Human pharmacokinetics are unusually well characterised for a peptide in this catalogue: Tmax 8-12 hours, absolute bioavailability around 55%, plasma protein binding over 98%, apparent volume of distribution around 13L, apparent clearance around 1.2 L/h. Degradation happens through general endogenous protein catabolism rather than a single clearance organ, with only trace liraglutide-related material recovered in urine and faeces.

The efficacy literature is human and large. The SCALE weight-management programme ran 3.0mg daily against placebo for 56 weeks in over 3,700 participants; LEADER ran cardiovascular outcomes in type 2 diabetes at up to 1.8mg. Read those as clinical pharmacology on the pharmaceutical article, not as claims about research-grade material.

Sourcing for Research

Liraglutide is far less commonly offered by research peptide suppliers than the weekly GLP-1 analogs, and availability is patchy. Where you do find it, source from suppliers that provide third-party testing and certificates of analysis (COA) for each batch, and check that the COA identifies the acylated peptide rather than a bare GLP-1 backbone. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Storage Requirements

Lyophilized (Powder)

• Temperature: -20°C or colder
• Duration: 2+ years
• Conditions: Dry, dark, protected from moisture

Reconstituted

• Temperature: 2-8°C (refrigerated)
• Duration: 4 weeks
• Conditions: Protected from light, never freeze

At daily dosing a 5mg vial empties long before the four-week window closes, so shelf life is rarely the binding constraint here — puncture count and sterile technique are.

Safety Considerations

• Liraglutide is covered here as a research compound
• Research use only — not for human consumption
• Research-grade material is not equivalent to a pharmaceutical preparation
• Use sterile technique; never reuse needles or syringes

Scientific References

1. Liraglutide injection prescribing information, clinical pharmacology section — elimination half-life ~13 h, Tmax 8-12 h, bioavailability ~55%, protein binding >98%. DailyMed.
2. Pi-Sunyer X, et al. “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.” N Engl J Med. 2015;373(1):11-22.
3. Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Front Endocrinol. 2019;10:155.

Last updated: 2026-07-21.

Disclaimer: This information is for educational and research purposes only. Research-grade liraglutide is not intended for human consumption. Always follow applicable laws and institutional guidelines.